BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Delgado-Borrego A, Kamegaya Y, Jordan SH, Agrawal S, Valim C, Chung RT. HCV synergizes with body weight in the promotion of insulin resistance. J Viral Hepat 2011;18:135-41. [PMID: 20497310 DOI: 10.1111/j.1365-2893.2010.01291.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Oliveira LP, de Jesus RP, Boulhosa RS, Onofre T, Mendes CM, Vinhas L, Waitzberg DL, Lemaire DC, Cavalcante LN, Lyra AC, Lyra LG. Factors Associated with Insulin Resistance in Patients with Chronic HCV Genotype 1 Infection without Obesity or Type 2 Diabetes. J Am Coll Nutr 2016;35:436-42. [PMID: 26933768 DOI: 10.1080/07315724.2015.1072756] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
2 Brandman D, Bacchetti P, Ayala CE, Maher JJ, Khalili M. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care. 2012;35:1090-1094. [PMID: 22399695 DOI: 10.2337/dc11-1837] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
3 Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016;10:1227-34. [DOI: 10.1080/17474124.2016.1234375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]